These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27182831)

  • 1. Influence of the treatment facility volume on the survival of patients with non-Hodgkin lymphoma.
    Go RS; Al-Hamadani M; Shah ND; Crowson CS; Holton SJ; Habermann EB
    Cancer; 2016 Aug; 122(16):2552-9. PubMed ID: 27182831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma.
    Go RS; Bartley AC; Crowson CS; Shah ND; Habermann EB; Holton SJ; Holmes DR
    J Clin Oncol; 2017 Feb; 35(6):598-604. PubMed ID: 28199819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.
    Goyal G; Kommalapati A; Bartley AC; Gunderson TM; Adjei AA; Go RS
    Lung Cancer; 2018 Aug; 122():214-219. PubMed ID: 30032834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between facility volume and mortality of patients with classic Hodgkin lymphoma.
    Goyal G; Tella SH; Funni S; Kommalapati A; Inselman JW; Shah ND; Go RS; Ansell SM
    Cancer; 2020 Feb; 126(4):757-764. PubMed ID: 31714588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in non-Hodgkin lymphoma survival between young adults and children.
    Tai E; Pollack LA; Townsend J; Li J; Steele CB; Richardson LC
    Arch Pediatr Adolesc Med; 2010 Mar; 164(3):218-24. PubMed ID: 20194253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia.
    Gunaratne MDSK; Sahakian AJ; Abeykoon JP; Ansell SM; Gertz MA; Kapoor P; Paulus A; Ailawadhi S; Reeder CB; Witzig TE; Habermann TM; Novak AJ; Lacy MQ; Kyle RA; Go RS; Paludo J
    Leuk Lymphoma; 2021 Feb; 62(2):308-315. PubMed ID: 33054437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.
    Bajaj A; Martin B; Bhasin R; Hentz C; Block AM; Harkenrider MM; Solanki AA
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):851-857. PubMed ID: 29485062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival trends in glioblastoma and association with treating facility volume.
    Aulakh S; DeDeo MR; Free J; Rosenfeld SS; Quinones-Hinojosa A; Paulus A; Manna A; Manochakian R; Chanan-Khan AA; Ailawadhi S
    J Clin Neurosci; 2019 Oct; 68():271-274. PubMed ID: 31133366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent socioeconomic inequalities in cancer survival in the United States: 1973-2007 surveillance, epidemiology and end results (SEER) data for breast cancer and non-Hodgkin's lymphoma.
    Kato I; Booza J; Quarshie WO; Schwartz K
    J Registry Manag; 2012; 39(4):158-66. PubMed ID: 23493021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residential proximity to industrial combustion facilities and risk of non-Hodgkin lymphoma: a case-control study.
    Pronk A; Nuckols JR; De Roos AJ; Airola M; Colt JS; Cerhan JR; Morton L; Cozen W; Severson R; Blair A; Cleverly D; Ward MH
    Environ Health; 2013 Feb; 12():20. PubMed ID: 23433489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival.
    Cheraghlou S; Agogo GO; Girardi M
    J Am Acad Dermatol; 2019 Apr; 80(4):979-989. PubMed ID: 30365997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facility Volume and Survival in Nasopharyngeal Carcinoma.
    Yoshida EJ; Luu M; David JM; Kim S; Mita A; Scher K; Shiao SL; Tighiouart M; Lee NY; Ho AS; Zumsteg ZS
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):408-417. PubMed ID: 29100787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.
    Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
    Am J Hematol; 2015 Aug; 90(8):696-701. PubMed ID: 25963924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group.
    d'Amore F; Brincker H; Grønbaek K; Thorling K; Pedersen M; Jensen MK; Andersen E; Pedersen NT; Mortensen LS
    J Clin Oncol; 1994 Aug; 12(8):1673-84. PubMed ID: 8040680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma.
    Gordon MJ; Duan Z; Zhao H; Nastoupil L; Iyer S; Ferrajoli A; Danilov AV; Giordano SH
    JCO Clin Cancer Inform; 2024 Apr; 8():e2300223. PubMed ID: 38684043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of facility volume on therapy and survival for locally advanced cervical cancer.
    Lin JF; Berger JL; Krivak TC; Beriwal S; Chan JK; Sukumvanich P; Monk BJ; Richard SD
    Gynecol Oncol; 2014 Feb; 132(2):416-22. PubMed ID: 24333361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adolescent weight and height are predictors of specific non-Hodgkin lymphoma subtypes among a cohort of 2,352,988 individuals aged 16 to 19 years.
    Leiba M; Leiba A; Keinan-Boker L; Avigdor A; Derazne E; Levine H; Kark JD
    Cancer; 2016 Apr; 122(7):1068-77. PubMed ID: 26900677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphoma.
    Pulte D; Jansen L; Brenner H
    Oncologist; 2015 May; 20(5):554-61. PubMed ID: 25876991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
    Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
    Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.
    Chen YW; Mahal BA; Muralidhar V; Nezolosky M; Beard CJ; Den RB; Feng FY; Hoffman KE; Martin NE; Orio PF; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):683-90. PubMed ID: 26972640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.